CARO 2016 _________________________________________________________________________________________________________ concentration of the metabolite in the cancer group (p = 0.040). Subsequently, EBC samples were analyzed by an LC-QTOF-Mass Spectroscopy (MS) using a non-targeted approach. A total of 625 compounds were detected in all EBC samples combined among which, four were up regulated in patients with lung cancer (TTest, p < 0.05). Conclusions: Lower concentrations of methanol (EBC), glycoprotein (sputum), absence of glucose in sputum identified through MRS and up regulation of four specific metabolites in EBC identified through MS in patients with known lung cancer suggest that MRS and MS may provide a lung cancer specific metabolic profile that can be used to develop a non-invasive tool to screen for lung cancer in high-risk population. Purpose: Non-small cell lung cancer (NSCLC) frequently progresses during the interval between diagnosis and initiation of radiation therapy. We have previously demonstrated that tumour growth rate (GR) is an important predictor of localregional control and survival in early lung cancer patients treated with SBRT using specific growth rate (SGR) as a metric for tumour growth rate, and its median (0.43x10-2) as a cut off to group patients into high and low SGR groups. The aim of this study was to: 1) validate SGR value of 0.43x10-2 as a metric for GR; and 2) determine the influence of pre-treatment tumour SGR on outcomes of early stage NSCLC patients treated with SBRT at a second institution. Methods and Materials: A retrospective chart review of 160 patients with pathologically confirmed T1-2 N0 NSCLC patients treated with SBRT between June 2010 and December 2012 was undertaken. Demographic and clinical data were collected from an institutional database. Time between diagnostic and simulation CT scans was calculated (t). Diagnostic CT was uploaded to Focal planning software v.4.70. Gross tumour was contoured on each slice using lung window to calculate Gross Tumour Volume (GTV1). The pre-treatment planning CT images were uploaded from archived files to record the pre-treatment GTV (GTV2). SGR was calculated using the equation: SGR = ln (GTV2/GTV1)/t). The SGR cut offv(0.43x10-2) from our previous data was used to group patients into two cohorts. Kaplan-Meier curves were constructed for both overall (OS) and failure-free survivals (FFS), and the log rank for comparison between high and low SGR groups. Multivariate analyses were performed using a Cox proportional hazard model with SGR and other relevant clinical factors. Results: Median time interval between initial diagnostic and planning CT scans was 87 days (range: 5-338). The median SGR was 0.418 x 10-2 (range -1.1x10-2; -5.1910-2). Median GTV1 was 3.5 cm 3 (range: 0.2; 51.9 cm 3 ) and median GTV2 was 6 cm 3 (range: 0.2; 79.1 cm 3 ). At median follow up period of 35.8 months, the median OS was 54 months. Three years OS was 60%. Patients were grouped into high and low SGR using previously reported SGR median as a cut off (0.43x10-2). The median survival was 30.3 months for high SGR versus 44.6 months for low SGR (p = 0.02). The median FFS was 36 months for high SGR versus 51.9 months for low SGR groups respectively (p < 0.01). On univariable analysis, gender (p = < 0.01), Stage T2 (p < 0.01), and GTV2 (p < 0.01) were also predictive for OS and FFS. On multivariate analysis only male gender (p = 0.006) and GTV2 (p = 0.04) were predictive for OS and high SGR (p = 0.01), male gender (p = < 0.01), and GTV2 (p = < 0.01) were independent predictors for poorer FFS. Conclusions: This analysis of an independent data set confirmed the validity of pre-treatment SGR. High SGR was associated with poorer outcome in patients with early stage NSCLC treated with SBRT. Further work to correlate and combine its use with biological markers is ongoing. 
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THE ROLE OF MID-TREATMENT 18F-FDG PET IN ASSESSING EARLY FUNCTIONAL RESPONSE AND PREDICTING OUTCOMES IN PATIENTS WITH LOCALLY ADVANCED NON-SMALL CELL LUNG CANCER UNDERGOING RADICAL CHEMORADIOTHERAPY

Conclusions:
Early metabolic response midway through radiotherapy as quantified by Δ TLG by 75% or more was associated with longer OS. SUVmax at baseline and midtreatment and Δ SUVmax were not associated with OS or PFS. Early identification of poor CRT responders may allow for future clinical trials to improve outcomes in these patients, such as dose escalation with an additional RT boost. Larger studies are needed to confirm these findings 
